Why the study?
Despite the rising prevalence of insulin resistance and its associated risks, there remains a notable gap in understanding the role of lncRNAs in clinical diabetes.
Does targeting lncRNA MALAT1 improve outcomes in patients with metabolic syndrome?
Does targeting lncRNA MALAT1 improve outcomes in patients with metabolic syndrome?
Targeting lncRNA MALAT1 represents a potential novel therapeutic approach for managing metabolic syndrome and its cardiovascular complications.
May support MALAT1 targeting in metabolic syndrome; leaves open validation in prospective trials before any clinical role.
Metabolic syndrome (MetS) is a collection of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. Recently, long noncoding RNAs (lncRNAs) have emerged as pivotal regulators of metabolic balance, influencing the genes associated with MetS. Although the prevalence of insulin resistance is rising, leading to an increased risk of type 2 diabetes mellitus (T2DM) and its vascular complications, there is still a notable gap in understanding the role of lncRNAs in the context of clinical diabetes. Among lncRNAs, lung adenocarcinoma metastasis-associated transcript 1 (MALAT1) has been identified as a significant regulator of metabolism-related disorders, including T2DM and cardiovascular disease (CVD). This review explores the mechanism of lncRNA MALAT1 and suggests that targeting it could offer a promising strategy to combat MetS, thereby enhancing the prognosis of MetS.
No takes yet. Share an insight, caveat, or question.
Aihemaiti et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: